Difference between revisions of "Team:NCTU Formosa"

Line 4: Line 4:
 
<link href="https://2015.igem.org/Team:NCTU_Formosa/wiki_reset?action=raw&ctype=text/css" rel="stylesheet">
 
<link href="https://2015.igem.org/Team:NCTU_Formosa/wiki_reset?action=raw&ctype=text/css" rel="stylesheet">
 
<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>
 
<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>
 +
<script>
 +
$(document).ready(function(){
 +
 
 +
    if($(".div3").innerHeight()<$(".div3-1").innerHeight()){
 +
        $(".div3").css("height",$(".div3-3").innerHeight());
 +
       
 +
    };
  
 +
});
 +
</script>
 
<style>
 
<style>
 
         body{
 
         body{
Line 36: Line 45:
 
         position:absolute;
 
         position:absolute;
 
         left:8%;
 
         left:8%;
−
height:100%;
+
 
top:0vh;
 
top:0vh;
 
         margin-left:0;  
 
         margin-left:0;  
Line 43: Line 52:
 
         background:#fff;
 
         background:#fff;
 
         width:28%;
 
         width:28%;
−
height:100%;
+
 
position:absolute;
 
position:absolute;
 
         left:36%;
 
         left:36%;
Line 52: Line 61:
 
         background:#fff;
 
         background:#fff;
 
         width:28%;
 
         width:28%;
−
height:100%;
+
 
position:absolute;
 
position:absolute;
 
         left:64%;
 
         left:64%;
Line 105: Line 114:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
−
text-align: justify;
+
text-align:left;
−
position:absolute;
+
margin-left : 8%;
−
top:50%;
+
−
left:8%;
+
−
height:50%;
+
 
width:80%;
 
width:80%;
 
}
 
}
Line 129: Line 135:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
−
text-align: justify;
+
text-align:left;
 
position:absolute;
 
position:absolute;
 
top:50%;
 
top:50%;
Line 152: Line 158:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
−
text-align: justify;
+
text-align:left;
 
position:absolute;
 
position:absolute;
 
top:50%;
 
top:50%;
Line 168: Line 174:
 
background-repeat: no-repeat;  
 
background-repeat: no-repeat;  
 
}
 
}
−
 
+
.div3 img{
 +
width:85%;
 +
margin-left:7.5%;
 +
}
 
</style>
 
</style>
 
   </head>
 
   </head>
Line 191: Line 200:
 
     <div class="div3 ">
 
     <div class="div3 ">
 
<div class="div3-1">
 
<div class="div3-1">
−
  <div class="photo3-1"></div>
+
−
         
+
          <img src="https://static.igem.org/mediawiki/2015/5/51/2015_NCTU_Formosa_Homepage_21.png" align="center" >  
 
      <div class="photocontent1"><h2>Who are we</h2>
 
      <div class="photocontent1"><h2>Who are we</h2>
 
         NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO     
 
         NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO     
−
         devoted to developing detection technology by uti-  lizing antibodies. In 2015, We cooperated with iGEM with Synthetic   
+
         devoted to developing detection technology by utilizing antibodies. In 2015, We cooperated with iGEM with Synthetic   
 
         Biology to develop a brand new detection platform. </div>
 
         Biology to develop a brand new detection platform. </div>
 
    </div>
 
    </div>
 
              
 
              
 
         <div class="div3-2">
 
         <div class="div3-2">
−
  <div class="photo3-2"></div>
+
    <img src="https://static.igem.org/mediawiki/2015/2/2e/NCTU_Formosa_Homepage_antibody.png" align="middle" >  
−
      <div class="photocontent2"><h2>What's new</h2>
+
      <div class="photocontent1"><h2>What's new</h2>
 
  APOllO E.Cotector:<br>   
 
  APOllO E.Cotector:<br>   
−
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen -antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
+
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
 
      </div> </div>
 
      </div> </div>
 
              
 
              
 
           <div class="div3-3">
 
           <div class="div3-3">
−
    <div class="photo3-3"></div>
+
    <img src="https://static.igem.org/mediawiki/2015/2/2c/Nctu_formosa_homepage_cell.png" align="middle" >  
 
             
 
             
−
        <div class="photocontent3"><h2>What do we care</h2>
+
        <div class="photocontent1"><h2>What do we care</h2>
 
         
 
         
 
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.<br>
 
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.<br>

Revision as of 14:08, 18 September 2015

The only thing we can detect is everything.

Who are we

NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO devoted to developing detection technology by utilizing antibodies. In 2015, We cooperated with iGEM with Synthetic Biology to develop a brand new detection platform.

What's new

APOllO E.Cotector:
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.

What do we care

In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.